FDA clears Allergan's Botox for treatment of overactive bladder

Allergan has obtained FDA approval for Botox (onabotulinumtoxinA) to treat overactive bladder (OAB) in adults who cannot tolerate or respond poorly to anticholinergic medication.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news